



BD to distribute AITbiotech Pte Ltd assays developed for the BD MAX™ System

BD enters into an agreement with AITbiotechPte Ltd for the distribution of AITbiotech *abTES*™ BM qPCR assays optimized on the BD MAX™ System

SINGAPORE – June 6, 2014 –BD (Becton, Dickinson and Company), a leading global medical technology company, has announced through its Singapore-based subsidiary, Becton Dickinson Holdings Pte Ltd, the signing of a distribution agreement with AITbiotech Pte Ltd, a leading manufacturer of molecular diagnostic (MDx) assays and provider of genomic services based in Singapore, for the distribution of AITbiotech *abTES*™ BM qPCR assays in the Asia Pacific region.

“Our agreement with AITbiotech represents a key milestone in BD’s strategy to make the BD MAX™ System an indispensable laboratory tool that empowers laboratory professionals to provide rapid and accurate test results,” said Glen Costin, Business Director Molecular & Cancer Diagnostics Asia Pacific, BD Diagnostics. “The fully automated BD MAX™ System has a content-rich menu with a flexible open mode capability and standardized workflows that enable laboratories to consolidate a broad range of molecular tests that meet both their current and future needs.”

AITbiotech *abTES*™ BM assays are developed to optimize applications on the BD MAX™ System. The *abTES*™ BM assays are manufactured at AITbiotech’s ISO13485 certified facilities in Singapore. At present, *abTES*™ BM Research Use Only assays are available for detection of *Chlamydia trachomatis*/*Neisseria gonorrhoeae* (CT/NG), Herpes Simplex Virus 1/Herpes Simplex Virus 2/Varicella Zoster Virus (HSV1/2/VZV) and *Mycobacterium tuberculosis* (MTB).

“We are extremely excited about the opportunity to work with a leading global MDx company like BD,” said Alex Thian, AITbiotech CEO. “AITbiotech, sees the opportunity to work with BD and its unique fully automated BD MAX™ System as a great way to expand our assay offering.”

About BD

BD is a leading global medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.

About AITbiotech

AITbiotech is a leading Genomic Services and MDx company based in Singapore. Founded by Alex Thian in 2008, it has a core molecular services and R&D laboratory in Singapore managed by a team of experienced biotechnologists. It provides a complete suite of Genomic Services including Oligonucleotides Synthesis, Capillary Sequencing, Next-generation Sequencing Services, Bioinformatics Services and customized molecular services to the research, healthcare and biomedical industries in Singapore and Asia. AITbiotech is also an ISO 13485 certified company which manufactures and distributes its own line of real-time PCR pathogen detection assays branded as *abTES*[™] in the Asian and European markets. For more information, please visit our website: www.aitbiotech.com.

Contacts:

Ms. Tan Shirley
Senior Business Director
AITbiotech Pte Ltd
+65 6778 6822
shirley@aitbiotech.com
www.aitbiotech.com

Ms. Lindsay Roman
Public Relations
BD
+1 (201) 847-4312
lindsay_roman@bd.com
www.bd.com